Venkat Jasti, Chairman and CEO, Suven Life Sciences interviewed by CNBC
Key Take away from interview:
- Q3 will be inline with Q2 numbers
- revenues will revive in Q4 on back of cyclical value-added products
- He expects 20-25 percent jump in revenues and EBITDA at 35-36 percent in Q4
- Value Added Products will give EBITA of 35-36% and Net Profit margin around 23-32%.
Read more at money control link given below:
| Subscribe To Our Free Newsletter |
